Skip to main content

Table 2 HIV-1 subtype and drug resistance mutations in patients

From: Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Cases Controls
KAF Subtype Mutationsa GSSa HIV-1 VL KAF Subtype Mutationsa GSSa HIV-1 VL
151 CRF02_AG 0 5.38 075 CRF02_AG 0 5.08
083 CRF02_AG 0 5.74 124 CRF02_AG 0 5.46
092 CRF02_AG 0 5.87 023 CRF01_AE na na 5.49
028 CRF02_AG 0 5.26 130 CRF02_AG/G 0 5.73
090 G 0 4.76 033 A/CRF01_AE V118I 0 6.02
056 G na na 5.33 081 CRF02_AG 0 5.39
071 CRF02_AG V108I, V179E 25 5.16 078 CRF02_AG E138A 0 3.52
120 CRF02_AG 0 5.65 104 G V108I 15 5.18
026 CRF02_AG 0 5.76 149 CRF02_AG 0 4.65
115 CRF02_AG 0 5.09 074 CRF02_AG 0 5.73
031 CRF02_AG V90I 0 4.87 137 A/CRF02_AG 0 5.28
061 CRF02_AG 0 5.86 010 CRF02_AG 0 6.33
077 CRF02_AG 0 5.52 064 na na na 6.45
041 G V108IV, E138A, V179EV 10 4.20 121 CRF02_AG 0 6.27
156 CRF02_AG 0 5.54 037 CRF02_AG 0 5.49
011 CRF02_AG V90I 0 5.31 095 CRF02_AG 0 6.15
109 CRF02_AG 0 6.08 019 G 0 6.16
200 na na na na 024 CRF02_AG 0 4.46
  1. KAF, patients ID; Cases, individuals infected with HIV and HBV; Controls, those infected with only HIV; Mutationsa/GSSa, HIV-1 drug resistance mutations/genotypic sensitivity scores (GSS) based on specific ARVs used by patients as determined by the Stanford database (analyzed on July 8, 2014); HIV-1 VL, pre-HAART HIV-1 plasma viral load. Subtypes were determined by the Stanford database
  2. na not available